KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Shares Outstanding (Weighted Average): 2017-2025

Historic Shares Outstanding (Weighted Average) for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to $314.1 million.

  • Amneal Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1.47% to $314.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $314.1 million, marking a year-over-year increase of 1.47%. This contributed to the annual value of $309.8 million for FY2024, which is 1.08% up from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $314.1 million, which was up 0.21% from $313.4 million recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Shares Outstanding (Weighted Average) peaked at $314.1 million during Q3 2025, and registered a low of $299.8 million during Q1 2021.
  • For the 3-year period, Amneal Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $308.6 million, with its median value being $308.7 million (2024).
  • Data for Amneal Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY increased of 1.54% (in 2025) over the last 5 years.
  • Amneal Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarterly) stood at $301.5 million in 2021, then grew by 0.70% to $303.6 million in 2022, then climbed by 0.97% to $306.5 million in 2023, then climbed by 1.08% to $309.8 million in 2024, then rose by 1.47% to $314.1 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $314.1 million in Q3 2025, compared to $313.4 million in Q2 2025 and $310.0 million in Q1 2025.